Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Clinical trial NCT05201638 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05201638
- Sponsor
- Immunic AG
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-12
- Primary completion
- 2026-11-01
- Enrollment
- 1100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.